The Dales Report is here with a psychedelics exclusive podcast. In this episode of Trade To Black with CEO Doug Drysdale, we catch up with Cybin’s latest developments, including FDA clearance for a Phase 2a study of CYB004 – and more.
2024 looks like there’s space for small cap growth, particularly in psychedelics and cannabis, so we’re keeping an eye on these industries. Cybin, (NYSE American: CYBN, NEO: CYBN), is one of the notable companies we’ve been keeping our finger on the pulse of, and we’re happy to have Doug Drysdale back at the mic with us to give us an update on their clinical trials and general outlook.
The big news is that this week Cybin announced FDA clearance to initiate a Phase 2a study of CYB004 in Generalized Anxiety Disorder (GAD). This will be a randomized, double-blind, active-controlled trial to assess the preliminary clinical efficacy, safety, tolerability, PK and PD of CYB004 in participants with GAD. We’ll discuss some of the timelines and other near-term catalysts in 2024 that will impact the study.
CYB004 is a proprietary deuterated DMT molecule. Gain insights from Doug Drysdale on these Phase 1 studies of CYB004 and SPL028, and their role in safer and more effective mental health treatments.
We also discuss the positive impact of CYB003, a deuterated psilocybin analogue, on MADRS scores. Late last year, the study on CYB003 and depression symptoms achieved its primary efficacy standpoint, with further numbers on a second dose.
Hear the thoughts from one of the leaders in the industry on the evolving landscape of mental health treatments, and how Cybin plans to revolutionize the field. We’ll also discuss the impact that legislative changes might have on advancing these kinds of psychedelic therapies. Don’t miss out on tuning in to this in-depth interview with Doug Drysdale of Cybin Inc.